AtheroGenics, Inc.{AGIX}-nasdaq Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AtheroGenics, Inc.{AGIX}-nasdaq

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: mlrb2113 who wrote (277)	6/29/2007 5:31:07 PM
From: Clarksterh	Read Replies (1) of 332

Mr. Clark: Dosages will be from 75 mg. to 300 mg. I would think they wouldn't go as low as 75 unless it has a chance of efficacy. Also, I'd think 75 would be very unlikely to show any toxicity. Mr Bob - Fancy seeing you over here! Yes, liver tox is often dose related. But so is efficacy. At the dose tested in ARISE 1067 has about the same efficacy as other diabetes drugs. But at doses of 1/4 the size the efficacy will probably be substantially less. That is the issue.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next